Form 4: GRI Bio CFO Kelly Granted Stock Options

GRI Bio, Inc.'s Chief Financial Officer, Leanne Kelly, was granted 43,222 stock options with an exercise price of $1.93.

Summary

• Leanne Kelly, Chief Financial Officer of GRI Bio, Inc. (GRI), was granted 43,222 stock options.
• The options have an exercise price of $1.93 per share.
• The transaction date for the grant was September 18, 2025.
• 29,923 shares vested in full upon the date of grant (September 18, 2025).
• The remaining 13,299 shares will vest in 12 substantially equal quarterly installments, leading to full vesting on the third anniversary of the grant date.
• The stock options have an expiration date of September 18, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive event, indicating executive alignment with shareholder interests and a commitment to long-term retention. It is a routine compensation event rather than a direct operational or financial performance indicator.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for executive retention and motivation.

Future Outlook

The vesting schedule for a portion of the options over three years indicates a forward-looking incentive structure designed to retain the Chief Financial Officer and align her performance with the company's long-term strategic goals.

Industry Context

The grant of stock options to a key executive like the Chief Financial Officer is a common practice in the biotechnology and pharmaceutical industries. This form of equity compensation is widely used to attract, retain, and motivate top talent by linking their financial success directly to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard practice for executive compensation in the biotech industry, aiming to align management incentives with shareholder value.
• The vesting schedule, with immediate vesting for a portion and time-based vesting for the remainder, is a common structure designed to encourage long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial incentives with shareholder value creation, potentially leading to better long-term performance. However, future exercise of options could lead to minor dilution.
• Employees: This reflects standard executive compensation practices, which can positively influence morale and retention for other key personnel.

Next Steps

• Continued vesting of the remaining 13,299 stock options over the next three years, subject to the Chief Financial Officer's continued employment.

Key Dates

Keywords

GRI Bio, GRI, Leanne Kelly, CFO, Stock Options, Equity Compensation, Insider Transaction, Form 4